Participated · Series A · Jun 2026

Bionyra is advancing a pipeline of next-generation mono- and multispecific antibodies engineered with half-life extension to target immune pathways in diseases with high unmet need. Lead programs include BYN-002, a TL1A monoclonal antibody in a fully enrolled Phase 1 in healthy subjects; BYN-003, a TL1A*IL-23p19 bispecific that entered Phase 1 in April; and BYN-001, an IL-25 monoclonal antibody in IND-stage for atopic dermatitis and type 2 inflammation. The company holds exclusive global rights to these assets outside Greater China through licenses from TrueLab Biopharmaceutical and NovaRock Biotherapeutics, and is progressing additional preclinical assets. Bionyra was co-founded and seed financed by Sofinnova Partners and is led by CEO Frédéric Marrache, a former Sanofi R&D executive with experience in immunology and inflammation. The company plans to use its Series A proceeds to advance clinical development and rapidly generate clinical validation in dermatology and inflammatory bowel disease.

Participated · Series C · Mar 2026

Cognito Therapeutics is a clinical-stage neurotechnology firm focused on creating neuroprotective, non-invasive therapies for central nervous system disorders. Its lead product, Spectris, is an at-home therapeutic platform that delivers sensory-driven neurostimulation to synchronize neural activity across interconnected brain networks. Feasibility studies indicate Spectris may preserve cognition, maintain daily function, and slow brain atrophy in patients with mild-to-moderate Alzheimer’s disease. The company plans to expand the Spectris platform into additional neurodegenerative indications through a network of brain-health collaboratories, beginning with the WVU Rockefeller Neuroscience Institute. Proceeds from its latest financing will fund these clinical expansions and further platform development. Although specific revenue or user numbers were not disclosed, the company positions itself as a late clinical-stage player nearing pivotal trials.

Participated · Series B · Dec 2025

Aeovian Pharmaceuticals is focused on restoring cellular metabolic quality control through highly selective inhibition of mTORC1 or CD38. Its lead candidate, AV078, is a first-in-class, CNS-penetrant selective mTORC1 inhibitor engineered to bypass the toxicities seen with non-selective mTOR blockers such as everolimus. Following encouraging Phase 1 data, AV078 is being advanced into a Phase 2 proof-of-concept trial for patients with TSC-related refractory epilepsy, a condition that affects roughly one million people worldwide and remains resistant to therapy in about two-thirds of cases. The company’s wholly owned pipeline aims to expand selective mTORC1 inhibition to additional rare and age-related indications. Proceeds from its recent financing will support the Phase 2 study and further pipeline development. Aeovian operates out of Berkeley, California and remains privately held; no revenue or user metrics were disclosed in the article.

Led · Seed · Nov 2025

Scripta Therapeutics combines experimental biology with artificial intelligence and advanced imaging to create and modulate disease maps based on transcriptional networks. By analysing patient-derived cellular models, the platform identifies nodes that can be targeted to shift diseased cells back to healthy phenotypes. Although broadly applicable, the company’s initial therapeutic focus is on Alzheimer’s disease and other neurodegenerative disorders, developed in collaboration with co-founder Professor Noel Buckley of the University of Oxford. The approach integrates wet-lab experimentation and computational analysis, positioning Scripta at the intersection of drug discovery and precision medicine. The recent seed financing provides $12 million of runway to expand operations and accelerate development programmes. No commercial products or revenue figures have been disclosed to date. The company’s leadership is headed by founder and CEO Peter Hamley, and its board now includes Ray Barlow as a non-executive director.

Participated · Seed · Jul 2025

Still Bright develops a vanadium-based electrochemical extraction system that soaks copper-containing ores in a regenerable vanadium solution to recover copper without the high-pollution pyrometallurgical steps. Inspired by vanadium flow batteries, the process electrically regenerates the spent solution and can recover nearly all copper from typical ores and from tailings. Its modular equipment is much smaller than traditional refiners because processing happens in minutes to an hour, enabling installations across a range of mine sizes. The company says its equipment costs 70–90% less than typical pyrometallurgical gear and currently runs at similar operating costs to a typical refinery, with expectations to become cheaper. Still Bright operates a pilot that produces about two tons of copper per year and plans a demonstration unit in 2027–2028 capable of producing 500 tons per year, targeting a commercial system of 10,000 tons annually. Founded in 2022 and based in New Jersey, Still Bright aims to scale to become one of the lowest-cost copper producers by enabling recovery from existing ores and waste streams.